Perospirone

Perospirone (Lullan) is an atypical antipsychotic of the azapirone chemical class. It was introduced in Japan in 2001 by Dainippon Sumitomo Pharma for the treatment of schizophrenia and acute bipolar mania. Perospirone acts as a 5-HT1A receptor partial agonist, 5-HT2A receptor inverse agonist, and D2, D4, and α1-adrenergic receptor antagonist.